Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Colleen E. Bennett, MD, MSHP and Cindy W. Christian, MD
When health care professionals encounter child abuse and neglect, they tend to experience a range of emotions, such as anger, sadness, and frustration.
AMA J Ethics. 2023;25(2):E109-115. doi:
10.1001/amajethics.2023.109.
Wendy G. Lane, MD, MPH and Rebecca R. Seltzer, MD, MHS
If it is ethically justifiable for clinicians to err by overreporting suspected abuse and neglect, we must fairly distribute benefits and harms among all children and families.
AMA J Ethics. 2023;25(2):E133-140. doi:
10.1001/amajethics.2023.133.